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When Pizzo et al. [1] reported the results
of their landmark study on the empirical
use of amphotericin B for treatment of
neutropenic patients with persistent, an-
tibiotics-refractory fever, they did not need
statistics. The results perfectly reflected the
prevailing perception enunciated by
DeGregorio et al. [2] and seemed to pro-
vide a rational basis for what became clin-
ical habit. As usual, the things that appear
absolutely logical are seldom true. How-
ever, it took a considerable length of time
before this concept of empirical antifungal
treatment showed the first cracks and
doubts emerged.
The need for empirical antifungal ther-
apy was distilled into a definition—
namely, any fever persisting for 3 or more
days despite broad-spectrum antibiotic
therapy while the patient was neutropenic.
In the meantime, we were presented with
4 large studies that compared the potential
of various new antifungal drugs for em-
pirical treatment [3–6]. Each drug vied to
attain the label for empirical use, although,
in fact, no substantial differences between
them were found [7]. Liposomal ampho-
tericin B and caspofungin won their spurs,
but voriconazole did not [5]. Thanks to
the quirks of statistics, we discovered that
the drug with the highest clinical anti-As-
pergillus activity could not be used for em-
pirical purposes because it did not fulfill
the criteria of “noninferiority” [8]. This
situation has changed considerably in the
past 30 years. High-resolution CT of the
chest is known to be superior to the tra-
ditional chest radiograph for detection of
pulmonary fungal disease [9]. It has also
been shown that systematic use of this
technique permits earlier diagnosis and
treatment and thus better rates of survival
[10]. The search for metabolites or cell
components of a given fungus, such as
specific antigens and DNA, led to some
crucial developments, the most important
of which was the ELISA test for galacto-
mannan, an antigen present in the Asper-
gillus cell wall [11]. Molecular techniques
based on PCR have not yet been validated
to a similar extent, but an overview of the
developments in the diagnostic field in-
dicates that timely discovery of an incip-
ient invasive fungal infection is becoming
feasible [12]. The newer diagnostics of-
fered the potential for an alternative to
empirical therapy, one that is commonly
referred to as the “preemptive” approach.
The seminal article of Maertens et al. [13]
showed that, by incorporating these new
diagnostic tools into their practice, it was
possible to reduce the rates of antifungal
therapy use by almost one-half, proving
that the principle was feasible. They also
proposed a randomized trial of preemp-
tive therapy versus empirical therapy to
confirm their findings, which one of us
(B.E.d.P.) found not to be a particularly
attractive idea [14].
In this issue, Cordonnier et al. [15] re-
port the results of their attempt to address
the question of whether a preemptive ap-
proach is equally effective as an empirical
approach in terms of overall survival. The
group chose patients they considered to
be at high risk of developing invasive fun-
gal disease but excluded allogeneic stem
cell transplant recipients. They anticipated
a survival rate of 90% for patients given
empirical therapy, and their hypothesis
was that preemptive therapy would not
prove to be inferior to empirical therapy
by 110%. Thus, 228 patients would need
to be assigned to each arm to achieve a
power of 80% with use of a 1-sided 95%
CI. The criteria adopted for starting em-
pirical therapy were persistent fever (13
days of fever and antibacterial therapy) or
recurrent fever. The criteria defined for
starting preemptive therapy included clin-
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ical signs and symptoms that might be
associated with fungal disease as well as
mycological evidence found at any time
after 4 days of fever and antibacterial ther-
apy. Mycological evidence included As-
pergillus colonization and galactomannan
antigenemia, defined by an optical density
1.5, rather than the now-current defi-
nition based on an optical density 0.5.
According to the primary outcome, there
was no difference in overall mortality be-
tween patients allocated to receive empir-
ical therapy and those allocated to receive
preemptive therapy. As expected, most pa-
tients in the empirical therapy group were
treated because of persistent fever. By con-
trast, most in the preemptive therapy
group started treatment because of pneu-
monia, and there were more cases of in-
vasive fungal disease due to both Asper-
gillus and Candida species in this group.
The other indications for preemptive ther-
apy, including septic shock, mucositis, and
galactomannan antigenemia, accounted
for very few indications. On average, pre-
emptive therapy was started almost 1 week
later than empirical therapy, but there
were no other essential differences be-
tween the 2 treatment groups. Impor-
tantly, most of the cases of invasive fungal
disease and related deaths occurred among
patients given induction chemotherapy
instead of consolidation therapy or an au-
tologous hematopoietic stem cell trans-
plant. This likely reflects the fact that the
outcome of invasive fungal disease de-
pends not only on timely intervention but
also on other factors, including the pro-
gression of the underlying disease [16]. On
the plus side, many fewer patients in the
preemptive therapy group received anti-
fungal therapy, resulting in less toxicity
and lower drug costs. In the trial, diag-
nostics were not applied as early or as vig-
orously as in the study by Maertens et al.
[13], and consequently, Cordonnier et al.
[15] were unable to provide the advantage
of the early detection of galactomannan
that Maertens and colleagues showed. The
study by Maertens et al. [13] also obtained
autopsy specimens for every fatal case,
whereas autopsies were not mentioned in
the study by Cordonnier et al. [15].
Cordonnier et al. [15] are to be com-
mended for their perseverance in com-
pleting what must have been a daunting
undertaking, given the climate of opinion
at the time. Their results are intriguing and
should help tilt the balance in favor of a
more diagnostic-driven approach to man-
agement of invasive fungal disease. Yet
they seem almost mesmerized by the
“noninferiority” of preemptive therapy for
patients receiving remission induction
therapy, to the extent that they overlook
their own observation that this approach
is at least perfectly suitable for patients
given chemotherapy either for consoli-
dation or to prepare for an autologous
stem cell transplantation. They make a
plea to investigate preemptive therapy fur-
ther, and we agree, provided that the trial
restricts itself to those patients at highest
risk—that is, those receiving remission in-
duction therapy. The diagnostic tools
available to us should be used more ju-
diciously in such a trial by screening pa-
tients from the moment that chemother-
apy is started. A PCR method to detect
fungal DNA may also prove to be useful,
as suggested by White et al. [17], who
found Aspergillus DNA in serial blood
samples from 6 of 40 patients with pos-
sible invasive fungal disease and 8 of 149
patients at risk for invasive fungal disease.
In their study among allogeneic stem cell
transplant recipients, Hebart et al. [18] de-
tected fungal DNA in almost one-half of
their preemptive therapy group. These re-
sults suggest that the presence of fungal
DNA and galactomannan antigenemia ap-
pear earlier than do signs and symptoms
of fungal disease and add weight to the
supposition that there is a transition from
infection to disease with respect to my-
cosis, as is apparent with viral infections.
A formal trial would be necessary to test
to clarify the advantages of the optimal
use of diagnostics. However, we have
doubts about seeking “noninferiority” to
empirical therapy since that found in the
current trial was very marginal indeed
leading to the question of whether “the
ball was over or on the line.” Rather, it
may be more important to compare a di-
agnostic-driven strategy with prophylaxis
as the former, appropriately executed, vir-
tually preempts the need for empirical an-
tifungal therapy. To us, this seems the best
way of “giving appropriate drugs to the
right person at the proper time” [19, p.
1186]. Whatever the strategy, it is also im-
portant not to forget that seeking a di-
agnosis does not stop with the initiation
of therapy because, even for cases with
negative findings, tests should be repeated
at regular intervals to identify potential
cases of emerging invasive fungal disease.
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